Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) issued its quarterly earnings data on Tuesday. The company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.29 by $0.02. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The firm had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same period in the prior year, the business posted $1.35 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) opened at 41.03 on Tuesday. The stock has a market capitalization of $37.50 billion, a P/E ratio of 27.41 and a beta of 0.73. Teva Pharmaceutical Industries has a 12-month low of $37.82 and a 12-month high of $66.55. The firm’s 50-day moving average is $43.93 and its 200 day moving average is $50.26.

Earnings History for Teva Pharmaceutical Industries (NYSE:TEVA)

A number of equities research analysts have issued reports on TEVA shares. RBC Capital Markets set a $71.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Sunday, September 11th. Bank of America Corp. set a $72.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Saturday, October 1st. Deutsche Bank AG set a $68.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Saturday, October 15th. Barclays PLC started coverage on shares of Teva Pharmaceutical Industries in a report on Monday. They set an “equal weight” rating and a $46.00 target price on the stock. Finally, Royal Bank Of Canada reduced their target price on shares of Teva Pharmaceutical Industries from $71.00 to $58.00 and set an “outperform” rating on the stock in a report on Monday. Ten research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $63.69.

A number of hedge funds have recently added to or reduced their stakes in TEVA. WFG Advisors LP raised its position in Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock valued at $104,000 after buying an additional 256 shares in the last quarter. Citizens Financial Group Inc RI raised its position in Teva Pharmaceutical Industries by 17.1% in the second quarter. Citizens Financial Group Inc RI now owns 2,398 shares of the company’s stock valued at $121,000 after buying an additional 351 shares in the last quarter. Krilogy Financial LLC raised its position in Teva Pharmaceutical Industries by 1.0% in the second quarter. Krilogy Financial LLC now owns 2,635 shares of the company’s stock valued at $132,000 after buying an additional 25 shares in the last quarter. SevenBridge Financial Group LLC purchased a new position in Teva Pharmaceutical Industries during the second quarter valued at approximately $159,000. Finally, WESPAC Advisors SoCal LLC raised its position in Teva Pharmaceutical Industries by 1.4% in the second quarter. WESPAC Advisors SoCal LLC now owns 3,550 shares of the company’s stock valued at $178,000 after buying an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 63.00% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.